Literature DB >> 9420275

Characterization of the CBF2 binding site within the Epstein-Barr virus latency C promoter and its role in modulating EBNA2-mediated transactivation.

E M Fuentes-Pananá1, P D Ling.   

Abstract

The Epstein-Barr virus (EBV) EBNA2 protein is a transcriptional activator that regulates viral and cellular gene expression and is also essential for EBV-driven immortalization of B lymphocytes. The EBNA2-responsive enhancer in the viral latency C promoter (Cp) binds two cellular factors, CBF1 and CBF2. The precise role of the CBF2 protein for Cp enhancer function is presently unclear. CBF2 does not appear to interact with EBNA2 and binds just downstream of CBF1 between positions -339 and -368 in the Cp EBNA2 enhancer. Within this region an 8-bp sequence, CAGTGCGT, can be found, and a similar sequence is also located downstream of CBF1 binding sites in other EBNA2-responsive promoters. Previous studies have indicated that mutations and methylation in this sequence affect EBNA2 responsiveness. To investigate the requirements for CBF2 binding, we synthesized a series of oligonucleotides carrying double transversion mutations spanning both the conserved core sequence and outside flanking sequences. Surprisingly, mutations outside of the conserved core sequence in 4 bases immediately flanking the 5' end, GGTT, had the most deleterious effect on CBF2 binding. Mutations in the conserved core had a gradient effect, with those near the 5' end having the most deleterious effects on CBF2 binding. In addition, the affinities of CBF2 for binding to the LMP-1, LMP-2, and CD23 promoters were also measured. These promoters contain the conserved core but lack the 5' flanking GGTT motif and bound CBF2 weakly or not at all. Using Cp reporter plasmids containing CBF2 mutant binding sites, we were also able to show that at lower doses of EBNA2, Cp transactivation required a functional CBF2 binding site but that higher doses of EBNA2 transactivated CBF2 mutant promoters to 40% of wild-type levels. These assays indicate that CBF2 is important for EBNA2-mediated transactivation of the viral latency Cp. In addition, CBF2 activity was found to be associated with two polypeptides of 27 and 33 kDa.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9420275      PMCID: PMC109424     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  53 in total

1.  Epstein-Barr virus nuclear protein 2 transactivates a cis-acting CD23 DNA element.

Authors:  F Wang; H Kikutani; S F Tsang; T Kishimoto; E Kieff
Journal:  J Virol       Date:  1991-08       Impact factor: 5.103

2.  Epstein-Barr virus nuclear antigen 2 activates transcription of the terminal protein gene.

Authors:  U Zimber-Strobl; K O Suentzenich; G Laux; D Eick; M Cordier; A Calender; M Billaud; G M Lenoir; G W Bornkamm
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

3.  EBNA-2 transactivates a lymphoid-specific enhancer in the BamHI C promoter of Epstein-Barr virus.

Authors:  N S Sung; S Kenney; D Gutsch; J S Pagano
Journal:  J Virol       Date:  1991-05       Impact factor: 5.103

4.  Epstein-Barr virus-encoded nuclear antigen 2 activates the viral latent membrane protein promoter by modulating the activity of a negative regulatory element.

Authors:  R Fåhraeus; A Jansson; A Ricksten; A Sjöblom; L Rymo
Journal:  Proc Natl Acad Sci U S A       Date:  1990-10       Impact factor: 11.205

5.  The level of c-fgr RNA is increased by EBNA-2, an Epstein-Barr virus gene required for B-cell immortalization.

Authors:  J C Knutson
Journal:  J Virol       Date:  1990-06       Impact factor: 5.103

6.  Promoter switching in Epstein-Barr virus during the initial stages of infection of B lymphocytes.

Authors:  M Woisetschlaeger; C N Yandava; L A Furmanski; J L Strominger; S H Speck
Journal:  Proc Natl Acad Sci U S A       Date:  1990-03       Impact factor: 11.205

7.  Early events in Epstein-Barr virus infection of human B lymphocytes.

Authors:  C Alfieri; M Birkenbach; E Kieff
Journal:  Virology       Date:  1991-04       Impact factor: 3.616

8.  Identification and characterization of an Epstein-Barr virus nuclear antigen 2-responsive cis element in the bidirectional promoter region of latent membrane protein and terminal protein 2 genes.

Authors:  G Laux; F Dugrillon; C Eckert; B Adam; U Zimber-Strobl; G W Bornkamm
Journal:  J Virol       Date:  1994-11       Impact factor: 5.103

9.  Role for the Epstein-Barr virus nuclear antigen 2 in viral promoter switching during initial stages of infection.

Authors:  M Woisetschlaeger; X W Jin; C N Yandava; L A Furmanski; J L Strominger; S H Speck
Journal:  Proc Natl Acad Sci U S A       Date:  1991-05-01       Impact factor: 11.205

10.  LEF-1, a gene encoding a lymphoid-specific protein with an HMG domain, regulates T-cell receptor alpha enhancer function [corrected].

Authors:  A Travis; A Amsterdam; C Belanger; R Grosschedl
Journal:  Genes Dev       Date:  1991-05       Impact factor: 11.361

View more
  14 in total

1.  Methylation status of the Epstein-Barr virus major latent promoter C in iatrogenic B cell lymphoproliferative disease. Application of PCR-based analysis.

Authors:  Q Tao; L J Swinnen; J Yang; G Srivastava; K D Robertson; R F Ambinder
Journal:  Am J Pathol       Date:  1999-08       Impact factor: 4.307

2.  A role for SKIP in EBNA2 activation of CBF1-repressed promoters.

Authors:  S Zhou; M Fujimuro; J J Hsieh; L Chen; S D Hayward
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

3.  Protein-DNA binding and CpG methylation at nucleotide resolution of latency-associated promoters Qp, Cp, and LMP1p of Epstein-Barr virus.

Authors:  D Salamon; M Takacs; D Ujvari; J Uhlig; H Wolf; J Minarovits; H H Niller
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

4.  Regulation of the Epstein-Barr virus C promoter by AUF1 and the cyclic AMP/protein kinase A signaling pathway.

Authors:  E M Fuentes-Pananá; R Peng; G Brewer; J Tan; P D Ling
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

5.  Sequence and functional analysis of EBNA-LP and EBNA2 proteins from nonhuman primate lymphocryptoviruses.

Authors:  R Peng; A V Gordadze; E M Fuentes Pananá; F Wang; J Zong; G S Hayward; J Tan; P D Ling
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

6.  Regulation of Epstein-Barr virus latency type by the chromatin boundary factor CTCF.

Authors:  Charles M Chau; Xiao-Yong Zhang; Steven B McMahon; Paul M Lieberman
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

7.  Neoplastic transformation by Notch requires nuclear localization.

Authors:  S Jeffries; A J Capobianco
Journal:  Mol Cell Biol       Date:  2000-06       Impact factor: 4.272

8.  Transcriptional activation signals found in the Epstein-Barr virus (EBV) latency C promoter are conserved in the latency C promoter sequences from baboon and Rhesus monkey EBV-like lymphocryptoviruses (cercopithicine herpesviruses 12 and 15).

Authors:  E M Fuentes-Pananá; S Swaminathan; P D Ling
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

9.  Methylation of adjacent CpG sites affects Sp1/Sp3 binding and activity in the p21(Cip1) promoter.

Authors:  Wei-Guo Zhu; Kanur Srinivasan; Zunyan Dai; Wenrui Duan; Lawrence J Druhan; Haiming Ding; Lisa Yee; Miguel A Villalona-Calero; Christoph Plass; Gregory A Otterson
Journal:  Mol Cell Biol       Date:  2003-06       Impact factor: 4.272

10.  Cell cycle association of the retinoblastoma protein Rb and the histone demethylase LSD1 with the Epstein-Barr virus latency promoter Cp.

Authors:  Charles M Chau; Zhong Deng; Hyojueng Kang; Paul M Lieberman
Journal:  J Virol       Date:  2008-01-23       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.